Novo Nordisk Alzheimer’s results to test GLP-1 potential
Source: www.reuters.com Key Points: Novo Nordisk Alzheimer’s trials are testing whether GLP-1 drugs like Rybelsus can slow cognitive decline in mild Alzheimer’s. The studies aim to clarify how GLP-1 drugs affect the brain and guide future research. Positive results could offer an oral alternative to current treatments and impact Novo’s market outlook. Studies from Novo Nordisk due early next month are expected to offer the clearest evidence so far on whether GLP-1 drugs, widely used for diabetes and weight loss, can slow cognitive decline in Alzheimer’s disease. The Novo Nordisk Alzheimer’s trials are evaluating the oral diabetes drug Rybelsus in two large trials involving thousands of people with mild Alzheimer’s. The data will be presented on Dec. 3 in San Diego at the Clinical Trials on Alzheimer’s Disease meeting. The studies aim to determine whether semaglutide, the active ingredient in Rybelsus, Ozempic and Wegovy, can reduce the rate of cognitive decline by at least 20%. Analyst...